Hanmi’s diabetic drugs featured in 2012 American Diabetes Association Meeting
Published: 2012-06-22 06:57:00
Updated: 2012-06-22 06:57:00
Hanmi Pharmaceutical Co. said Wednesday that the clinical utility of the Company’s LAPSCOVERY-based lead diabetic drugs, LAPS-Exendin4 and LAPS-Insulin, was featured at the Annual Scientific Sessions of the American Diabetes Association (ADA) being held June 9-11 in Philadelphia.
“This present...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
